Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01738698 · ClinicalTrials.gov registry record · Phase 3
Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT01738698 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 4 participants.
The verdict
NCT01738698, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).
Interventions
- DRUG Placebo
- DRUG SPD489 40mg
- DRUG SPD489 100mg
- DRUG SPD489 160mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-11-01 |
| Est. Completion | 2013-04-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01738698
The ClinicalTrials.gov registry entry for NCT01738698 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01738698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01738698 about?
NCT01738698 is a clinical study titled "Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia". The primary purpose of this study is to determine whether SPD489 40 mg, 100 mg, and 160 mg are effective and safe in the treatment of Negative Symptoms of Schizophrenia (NSS).
What is the current status of trial NCT01738698?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2012-11-01. Estimated completion is 2013-04-01.
What interventions are being tested in trial NCT01738698?
The interventions under investigation include: Placebo (DRUG), SPD489 40mg (DRUG), SPD489 100mg (DRUG), SPD489 160mg (DRUG).
Who is sponsoring clinical trial NCT01738698?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.